Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part

Next Previous
Trial Profile

A Phase 3, Multinational, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy PK, Kinetics and Safety of Aramchol in Nonalcoholic Steatohepatitis (NASH) With Open-Label Part

Status: Suspended
Phase of Trial: Phase III

Latest Information Update: 13 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Icomidocholic acid (Primary)
  • Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
  • Focus Registrational; Therapeutic Use
  • Acronyms ARMOR
  • Sponsors Galmed Research and Development, Ltd.

Most Recent Events

  • 01 Dec 2025 According to a Galmed Pharmaceuticals media release, Results were published in March 2025 in the prestigious Journal of Hepatology (Impact Factor of 33.0).
  • 16 Dec 2024 Planned End Date changed from 1 Jun 2027 to 30 Jun 2027.
  • 25 Sep 2024 According to a Galmed Pharmaceuticals media release results of the Open-Label part (ARCON ) of its global Phase 3 trial were published in the open access journal Hepatology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top